01Approach to the Critical Patient/attcp63

Immediate priorities

›Airway and breathing threats

›Severe hypoxemia on room air

›SpO2 <90% unresponsive to low-flow O2

›PaO2 <60 mmHg on ABG

›Ventilatory failure

›Rising PaCO2 with acidosis

›Increasing work of breathing and fatigue

›Altered mental status threatening airway

›GCS <9 or rapid deterioration

›If airway unprotected, proceed to rapid sequence intubation

›Hemodynamic instability

›Shock criteria

›SBP <90 mmHg or MAP <65 mmHg

›Right ventricular failure from acute pulmonary hypertension

›Resuscitation targets

›Euvolemia with balanced IV crystalloid

›Vasopressor initiation (norepinephrine) for refractory hypotension

›Avoid aggressive fluid overload

›Worsens pulmonary edema in FES-related ARDS

›Key early branching decision

›Classic post-fracture presentation

›Symptom onset 24–72 hours after long bone or pelvic fracture

›Triad: hypoxemia + neurologic change + petechiae

›Atypical FES

›Post-liposuction onset as early as 1.8 hours

›Sickle cell crisis with bone marrow necrosis

›Urgent rule-out of PE

02History/hx60

Presentation pattern

›Classic symptom triad

›Respiratory distress

›Dyspnea and tachypnea as earliest manifestation

›Often onset within 24–72 hours of inciting event

›Neurologic dysfunction

›Confusion, agitation, or obtundation

›Seizures or focal deficits in cerebral FES

›Petechial rash

›Upper chest, axillae, neck, conjunctivae

›Present in only 50–60% of cases; may appear last

›Symptom timeline

›Inciting event to symptom onset

›Long bone fracture: typically 24–72 hours

›Liposuction: may appear within 1.8 hours

›Intramedullary nailing: intraoperative or within 12 hours

›Progression sequence

›Tachypnea and hypoxemia first

›Confusion or agitation second

›Petechiae last or absent

Risk factors and inciting events

›Traumatic causes

›Long bone fractures (femur highest risk)

›Incidence of FES 0.5–11% after long bone fractures

›Multiple fractures increase risk proportionally

›Pelvic fractures

›High Injury Severity Score

›Delayed fracture fixation beyond 24 hours

03Physical Exam/exam63

Vitals and hemodynamic assessment

›Vital sign pattern

›Tachypnea

›Respiratory rate >20 often earliest finding

›Rate >30 as severity marker

›Tachycardia

›Sinus tachycardia most common

›Rate >120 suggests hemodynamic compromise

›Fever

›Temperature >38.5 degrees C typical

›Non-infectious pyrexia from fat-induced inflammation

›Hypoxemia

›SpO2 <90% on room air

›PaO2 <60 mmHg on ABG (major Gurd criterion)

›Hypotension

›SBP <90 mmHg in severe cases

›Indicates right ventricular failure or distributive shock

Pulmonary and cardiovascular exam

›Chest exam findings

›Bilateral crackles

›Diffuse distribution in ARDS pattern

›Absence of localizing consolidation

›Increased work of breathing

›Accessory muscle use

›Inability to speak in full sentences

›Cardiovascular findings

›Signs of right heart strain

›Elevated JVP

04Differential Diagnosis/ddx42

Life-threatening mimics

›Pulmonary thromboembolism

›ICD-10 I26.99

›CTA shows intraluminal filling defects (absent in FES)

›FES typically CTA-negative for thrombus

›ARDS from other cause

›ICD-10 J80

›Sepsis, aspiration, or transfusion-related ARDS

›FES-ARDS has characteristic post-fracture timing

›Traumatic brain injury

›ICD-10 S09.90XA

›Must be excluded with CT head in polytrauma

›FES can coexist with TBI

›Acute ischemic stroke

›ICD-10 I63.9

›FES produces MRI starfield pattern vs territorial infarct

›Cerebral fat emboli are multifocal and watershed in distribution

Common mimics

›Sepsis and pneumonia

›ICD-10 A41.9

›Fever and bilateral infiltrates overlap with FES

›FES has petechiae and characteristic fracture timing

›Air embolism

›Especially post-procedural

›Imaging shows intravascular air not fat

›Acute chest syndrome (sickle cell)

›ICD-10 D57.00

›Significant overlap with SCD-related FES

05Laboratory Tests/lt58

Core diagnostic labs

›Arterial blood gas

›Hypoxemia threshold

›PaO2 <60 mmHg meets Gurd major criterion

›PaO2/FiO2 <300 suggests ARDS spectrum

›Serial ABGs essential for monitoring trajectory

›Respiratory alkalosis early

›Compensatory hyperventilation

›Transition to acidosis signals decompensation

›Complete blood count

›Anemia

›Unexplained drop in hemoglobin (Gurd minor criterion)

›Microangiopathic pattern in severe cases

›Thrombocytopenia

›Platelet consumption by fat globule interaction

›Severity correlates with FES severity

›Coagulation panel

›D-dimer elevated

›Reflects microthrombus formation

›Not discriminatory between FES and PE

›Fibrin split products elevated

›Marker of disseminated intravascular coagulation risk

›PT and PTT monitoring

›DIC surveillance in severe cases

Inflammatory and metabolic labs

›Inflammatory markers

›C-reactive protein

›Elevated in proportion to severity

06Diagnostic Tests/dt106

Scoring Systems

›Gurd and Wilson criteria (most widely used)

›Major criteria (at least 1 required for diagnosis)

›Petechial rash in typical distribution

›Respiratory insufficiency (PaO2 <60 mmHg on FiO2 >0.4)

›Cerebral involvement not attributable to other cause

›Minor criteria (at least 4 required)

›Heart rate >120 beats per minute

›Fever >38.5 degrees C

›Retinal changes on fundoscopy

›Fat globules in urine

›Unexplained drop in Hgb >20 g/L

›Unexplained thrombocytopenia (platelet drop >50%)

›Elevated ESR >71 mm/hr

›Fat macroglobulinemia

›Clinical utility

›Sensitive but complex; incomplete FES may not meet full criteria

›Diagnosis supported clinically even without all criteria met

›Schonfeld Fat Embolism Index

›Quantitative scoring with weighted criteria

›Petechiae: 5 points

›Diffuse alveolar infiltrates on CXR: 4 points

›Hypoxemia (PaO2 <9.3 kPa / 70 mmHg): 3 points

›Fever >38 degrees C: 1 point

›Tachycardia >120 bpm: 1 point

›Tachypnea >30/min: 1 point

›Confusion: 1 point

›Score >=5 suggests FES

›Higher specificity than Gurd criteria alone

›Useful for quantifying severity and tracking response

MRI

›Brain MRI with DWI (most sensitive for cerebral FES)

›Starfield pattern on diffusion-weighted imaging

›Scattered punctate high-signal lesions in white matter

›Represents cytotoxic edema from microemboli

›Highly characteristic and differentiates from territorial infarct

›Lesions may persist on MRI even after clinical recovery of consciousness

›Distribution of lesions

›Watershed zones and deep white matter

›Corpus callosum, basal ganglia, brainstem involvement

›Bilateral symmetrical involvement typical

›FLAIR sequences

›Hyperintense signal may lag DWI findings

›Useful for following lesion evolution

›MR spectroscopy

›Lipid peak on spectroscopy supports fat embolism diagnosis

›Research tool; not routine in most centers

›MRI limitations

›Not immediately available in acute trauma settings

›CT used first to exclude hemorrhage and TBI

›Contraindicated with certain implants or ferromagnetic hardware

CT

›Chest CT

›Characteristic pulmonary findings

›Diffuse bilateral ground-glass opacities (most common, ~90%)

›Interlobular septal thickening

›Ill-defined centrilobular nodules

›Patchy consolidation in lower lobes

›Pattern evolution

›Early: ground-glass opacities predominate

›Late: consolidation and septal thickening predominate

›Chest CT vs plain radiograph

›CT identifies abnormalities when CXR still normal

›Plain CXR may be normal early despite severe hypoxemia

›CT pulmonary angiography

›Indication: rule out concurrent PE

›FES typically shows no intraluminal filling defects

›Normal CTA does not exclude FES

›Right heart assessment

›RV enlargement

›Interventricular septal bowing

›Brain CT

›Acute use in trauma to exclude hemorrhage and TBI

›Multiple small hypodense lesions may be seen in cerebral FES

›Less sensitive than MRI for early detection

›CT angiography of cerebral vessels

›Rules out large vessel occlusion mimicking stroke

›Fat emboli are microemboli; no large vessel filling defects

Ultrasound

›Echocardiography (bedside or formal TTE/TEE)

›Right ventricular assessment

›RV dilatation from acute pulmonary hypertension

›Interventricular septal flattening (D-sign)

›Tricuspid regurgitation with elevated RVSP

›Echogenic material in cardiac chambers

›Fat globules may appear as hyperechoic material

›Transient and may not always be visible

›Patent foramen ovale assessment

›Bubble study (agitated saline contrast)

›PFO allows paradoxical systemic embolism

›Increases risk of cerebral FES

›Pericardial effusion exclusion

›Point-of-care ultrasound (POCUS)

›Lung POCUS findings

›B-lines suggesting interstitial edema

›Bilateral involvement consistent with ARDS pattern

›Absence of pleural effusion in most FES cases

›IVC assessment

›Volume responsiveness estimation

›Guides fluid resuscitation strategy

›Transcranial Doppler

›Microembolic signals (HITS) in cerebral circulation

›High-intensity transient signals indicate fat microemboli

›Presence associated with PFO and cerebral involvement

›Bubble study via TCD

›Right-to-left shunting detection

›Confirms PFO contribution to cerebral FES

›Clinical utility

›Research and specialized centers

›Not routinely available in most emergency departments

07Disposition/dispo33

ICU admission

›ICU admission indications

›All confirmed or highly suspected FES cases

›FES is an ICU-level diagnosis by nature

›Class I recommendation based on severity potential

›Specific ICU triggers

›Mechanical ventilation requirement

›Altered mental status or coma

›Hemodynamic instability requiring vasopressors

›PaO2/FiO2 <300 (ARDS spectrum)

›Stepdown unit consideration

›Mild isolated hypoxemia with high clinical suspicion

›Serial ABGs and close neurologic monitoring mandatory

Transfer criteria

›Transfer indications

›Cerebral FES requiring neurology or neurocritical care

›Seizures requiring continuous EEG monitoring

›Focal deficits requiring neurosurgical evaluation

›SCD-related FES requiring exchange transfusion

›Hematology center with apheresis capability

›ECMO consideration in refractory ARDS

›Transfer to ECMO-capable center if conventional ventilation failing

Discharge criteria

›Safe discharge requirements

›Resolution of hypoxemia

›SpO2 >92% on room air for >12 hours

›Stable or resolved neurologic status

›Return to baseline mental status

08Treatment/t98

Respiratory support

›Supplemental oxygen

›Low-flow oxygen for mild hypoxemia

›Nasal cannula titrated to SpO2 target >92%

›Avoid hyperoxia (target SpO2 92–96%)

›High-flow nasal cannula

›HFNC for moderate hypoxemia before intubation

›Flow rates 30–60 L/min with FiO2 titrated to target

›Mechanical ventilation

›Indication: respiratory failure unresponsive to non-invasive support

›Rapid sequence intubation preferred

›Early intubation before fatigue-driven respiratory arrest

›Lung-protective ventilation strategy

›Tidal volume 6 mL/kg ideal body weight

›Plateau pressure <30 cmH2O

›PEEP titration per ARDS protocol

›Class I recommendation for ARDS ventilation

›PEEP targets

›Start at 5–8 cmH2O; titrate to oxygenation and hemodynamics

›Higher PEEP (12–16 cmH2O) in moderate-severe ARDS

›Monitor for RV failure with increasing PEEP

›Prone positioning

›If PaO2/FiO2 <150 mmHg on FiO2 >0.6

›16–18 hour prone cycles per ARDS network protocol

›Class I recommendation for severe ARDS

Hemodynamic management

›Fluid resuscitation

›Goal euvolemia not hypervolemia

›Balanced crystalloid (Lactated Ringer's) preferred

›Avoid aggressive fluid overload; worsens pulmonary edema

›Fluid responsiveness assessment

›POCUS IVC assessment or passive leg raise

›Limit to 250–500 mL boluses with reassessment

›Vasopressors for refractory hypotension

›Norepinephrine first-line

›Starting dose 0.05–0.1 mcg/kg/min IV infusion

›Titrate to MAP target >65 mmHg

›Maximum 0.5–1 mcg/kg/min before considering second agent

›Vasopressin adjunct

›0.03–0.04 units/min IV infusion

›Use when norepinephrine exceeds 0.25 mcg/kg/min

›Right ventricular failure management

›Inhaled nitric oxide

›5–40 ppm for severe RV failure with pulmonary hypertension

›Reduces RV afterload without systemic hypotension

›Avoid excess PEEP in RV failure

›High PEEP increases RV afterload

Pharmacologic therapies

›Corticosteroids

›Methylprednisolone IV

›Prophylactic regimen: 1.5 mg/kg IV every 8 hours

›Therapeutic regimen: 250 mg–1 g IV pulse

›Duration typically 3–5 days based on response

›Evidence debated; may reduce inflammation and improve hemodynamics

›No definitive RCT confirming mortality benefit

›Mechanism of benefit

›Reduces free fatty acid inflammatory cascade

›Stabilizes capillary membranes

›Decreases platelet aggregation

›Considerations

›Hyperglycemia monitoring required

›Infection risk in prolonged use

›VTE prophylaxis

›Standard DVT prophylaxis per trauma protocols

›Low molecular weight heparin when hemostasis assured

›Enoxaparin 40 mg SC daily (adjust for renal function)

›Mechanical prophylaxis

›Sequential compression devices for contraindicated anticoagulation

›Heparin

›Full therapeutic anticoagulation not routinely recommended

›Benefit unproven; potential hemorrhagic risk in trauma

›Not standard of care for FES

›High-intensity statins

›Empiric use in cerebral FES in some centers

›Trend toward decreased microembolic signals on TCD

›Not yet supported by definitive trial data

Supportive ICU care

›Standard ICU supportive measures

›Stress ulcer prophylaxis

›Pantoprazole 40 mg IV daily in ventilated patients

›Glycemic control

›Target blood glucose 7.8–10 mmol/L

›Insulin infusion if persistent hyperglycemia

›Early enteral nutrition

›Initiate within 24–48 hours of ICU admission when hemodynamically stable

›NPO if intubation anticipated or altered mental status present

›Seizure management

›Benzodiazepines for acute seizure termination

›Levetiracetam or valproate for seizure prophylaxis in cerebral FES

›Neurology consultation for refractory seizures

Surgical and preventive treatment

›Early fracture fixation

›Definitive fixation within 24 hours

›Reduces FES incidence by up to fivefold

›WSES-AAST guideline recommendation

›Intraoperative precautions

›Minimize intramedullary pressure during reaming

›Venting of medullary canal to reduce fat embolization

›SCD-related FES treatment

›Exchange transfusion (mainstay of treatment)

›Target HbS <30% post-exchange

›Reduces circulating sickle cells and fat emboli

›Hematology and apheresis consultation required

09Special Populations/sp82

Pregnancy

›Epidemiology in pregnancy

›FES rare in pregnancy; primarily traumatic causes

›Pelvic fractures in high-energy trauma most common trigger

›Amniotic fluid embolism is primary obstetric mimic (distinct entity)

›Non-traumatic FES in pregnancy

›Liposuction during pregnancy: contraindicated

›Bone marrow necrosis from SCD in pregnancy

›Physiologic considerations

›Pregnancy-related changes affecting management

›Increased baseline minute ventilation (PaCO2 normally ~30 mmHg)

›Elevated diaphragm reduces lung reserve

›Increased blood volume and cardiac output may mask early hemodynamic compromise

›Supine hypotension syndrome

›Left lateral decubitus positioning for aortocaval decompression

›Medication safety

›Corticosteroids

›Methylprednisolone acceptable in pregnancy (Category C)

›Fetal risk minimal with short-course therapeutic doses

›Norepinephrine

›Preferred vasopressor in pregnancy (maintains uteroplacental flow)

›Dopamine less preferred due to vasoconstriction risk

›Anticoagulation

›Low molecular weight heparin preferred (does not cross placenta)

›Warfarin contraindicated in first trimester

›Fetal monitoring

›Continuous fetal monitoring if viable gestation

›Obstetric consultation for any pregnant FES patient

›Delivery timing decision based on fetal status and maternal stability

Geriatric

›Epidemiology in elderly

›Femoral neck and intertrochanteric fractures predominate

›FES after hip fracture in elderly: underdisplaced fractures may still cause FES

›Delayed fixation common due to anticoagulation reversal needs

›Higher baseline comorbidity burden increases severity

›Physiologic considerations

›Reduced respiratory reserve

›Lower PaO2 at baseline (expected PaO2 = 100 - 0.3 x age in mmHg)

›Earlier intubation threshold warranted

›Cognitive baseline

›Dementia may mask neurologic changes of cerebral FES

›Collateral history essential for baseline mental status

›Cardiovascular reserve

›Diastolic dysfunction limits fluid tolerance

›Higher risk of volume overload with resuscitation

›Medication considerations

›Corticosteroid caution

›Hyperglycemia more pronounced in diabetics

›Delirium risk increases with steroids in elderly

›Anticoagulation dosing

›Reduced renal clearance: adjust LMWH for creatinine clearance <30 mL/min

›Fondaparinux alternative if heparin-induced thrombocytopenia risk

›Vasopressor sensitivity

›Lower starting doses; titrate carefully

›Arterial line placement for accurate titration

›Prognosis considerations

›Higher in-hospital mortality vs younger patients

›Prolonged neurologic recovery expected

›Early goals-of-care discussion if prognosis uncertain

Pediatrics

›Epidemiology in children

›Rare but recognized

›FES after knee arthroscopy reported in pediatric patients

›Long bone fractures in high-energy trauma

›SCD-related FES increasingly recognized in pediatric SCD patients

›Liposuction-related FES not applicable to pediatric population

›Clinical differences from adults

›Higher physiologic reserve may delay recognition

›Initial vital signs may appear preserved despite significant disease

›Rapid decompensation can occur suddenly

›Petechiae may be more readily visible in children

›Seizures more common manifestation than in adults

›Weight-based dosing

›Methylprednisolone

›1–2 mg/kg IV every 6–8 hours (therapeutic)

›Maximum 1 g per dose for pulse therapy

›Norepinephrine

›0.05–2 mcg/kg/min IV titrated to MAP target

›Enoxaparin VTE prophylaxis

›0.5 mg/kg SC every 12 hours for age >2 months

›Anti-Xa level monitoring target 0.5–1.0 units/mL

›Ventilation in children

›Lung-protective tidal volume 6–8 mL/kg IBW

›Pediatric ARDS criteria (PALICC definition) for PEEP and oxygenation targets

›Pediatric critical care consultation mandatory

10Background/b98

Epidemiology

›Incidence and prevalence

›Overall FES incidence after long bone fractures

›Range 0.5–11% depending on definition and surveillance intensity

›Subclinical fat embolism occurs in majority of fracture patients

›Clinical FES represents minority of fat embolism events

›Fracture type specific incidence

›Femoral fractures: highest risk (up to 11%)

›Tibial fractures: 1–5%

›Multiple fractures: additive risk

›Liposuction-related FES

›Increasingly recognized, especially with large-volume procedures

›Rapid onset relative to traumatic FES

›Mortality and morbidity

›Overall FES mortality

›Ranges 5–18% in severe cases

›Most patients recover with supportive care

›Cerebral FES prognosis

›57% mild-to-moderate disability in case series

›Even comatose patients may achieve favorable neurologic recovery

›Consciousness recovery may precede MRI lesion resolution

›Demographics

›Young males predominate (higher fracture incidence in this group)

›No racial predilection except SCD-related FES

Pathophysiology

›Mechanical theory (primary mechanism)

›Fat droplet embolization

›Increased intramedullary pressure during fracture or manipulation

›Fat from bone marrow sinusoids enters venous circulation

›Emboli lodge in pulmonary microvasculature

›Pulmonary effects

›Mechanical obstruction of capillaries

›Increased pulmonary vascular resistance

›Right ventricular pressure overload

›Biochemical theory (secondary amplification)

›Free fatty acid release

›Lipases hydrolyze neutral fat into free fatty acids

›Free fatty acids cause direct endothelial damage

›Inflammatory cascade activation (IL-6, TNF-alpha)

›Platelet and coagulation activation

›Platelet aggregation on fat droplet surfaces

›Thrombocytopenia from platelet consumption

›DIC in severe cases

›Systemic inflammatory response

›Non-infectious pyrexia from lipid-mediated inflammation

›Capillary leak syndrome causing pulmonary and cerebral edema

›Paradoxical embolism mechanism

›Patent foramen ovale role

›Fat emboli traverse PFO to systemic circulation

›Direct cerebral embolism without primary pulmonary injury

›PFO detected in significant proportion of cerebral FES patients

›Cerebral effects

›Cytotoxic edema from fat microemboli in cerebral microvasculature

›Starfield pattern on DWI reflects scattered infarct zones

›Watershed distribution from hypoperfusion superimposed on embolism

›SCD-specific pathophysiology

›Bone marrow necrosis

›Vaso-occlusive crisis causes ischemia of bone marrow fat

›Necrotic marrow fat released into circulation

›Simultaneous acute chest syndrome and FES overlap common

Therapeutic Considerations

›No specific pharmacologic cure exists

›Management is primarily supportive

›Oxygen delivery optimization

›Hemodynamic support

›Organ-supportive ICU care

›Early fracture fixation is the most evidence-supported intervention

›Reduces embolization by removing fracture site as fat source

›WSES-AAST 2025 guideline: fixation within 24 hours

›Corticosteroid controversy

›Proposed mechanisms of benefit

›Membrane stabilization reducing capillary leak

›Reduction of free fatty acid inflammatory cascade

›Platelet aggregation inhibition

›Evidence limitations

›No large definitive RCT confirming mortality benefit

›Small studies and case reports suggest hemodynamic improvement

›Prophylactic use more evidence-supported than therapeutic use

›ARDS management evidence

›Lung-protective ventilation

›Class I recommendation based on ARDS Network trials

›Applicable to FES-ARDS as for other ARDS causes

›Conservative fluid management

›Reduces duration of mechanical ventilation in ARDS

›Applies to FES-ARDS management strategy

›Exchange transfusion in SCD-FES

›Reduces HbS percentage and fat embolism load

›Target HbS <30% post-exchange

›Improves oxygenation and neurologic recovery

›Evidence from SCD acute chest syndrome literature

›Extrapolated to SCD-related FES given overlapping pathophysiology

›Prevention strategy

›Early fracture stabilization

›Within 24 hours of injury when hemodynamically feasible

›Reduces FES incidence by up to fivefold

›Prophylactic corticosteroids

›Methylprednisolone 1.5 mg/kg IV prior to intramedullary nailing

›Evidence base limited but practice supported in high-risk cases

›Surgical technique optimization

›Venting of medullary canal before reaming

›Minimizing cement pressurization in arthroplasty

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Discharge instructions for Fat Embolism Syndrome

›What happened to you

›You developed fat embolism syndrome, a complication of your fracture or procedure

›Tiny fat droplets from your bone marrow entered your bloodstream and affected your lungs and brain

›Most people recover fully with supportive treatment

›Medications

›Take all prescribed medications exactly as instructed

›Do not stop any new medications without discussing with your doctor first

›Seek medical advice before starting new medications including blood thinners

›Activity restrictions

›Follow your orthopedic surgeon's weight-bearing and activity restrictions

›Do not drive while taking sedating medications

›Avoid strenuous activity until cleared by your medical team

›Expected recovery

›Lung function typically improves over days to weeks

›Neurologic deficits (memory, concentration) may take weeks to months to improve

›Some patients have persistent mild cognitive symptoms for months

›Brain MRI lesions may persist even after you feel better

›Follow-up appointments

›Attend all scheduled follow-up appointments with your primary physician

›Neurology follow-up if you had confusion, seizures, or memory problems during hospitalization

›Cardiology follow-up if a hole in your heart (patent foramen ovale) was identified

›Orthopedic surgery follow-up for fracture healing assessment

›Return to emergency department immediately for

›New or worsening shortness of breath or difficulty breathing

›New confusion, drowsiness, difficulty speaking, or weakness in an arm or leg

›Seizures or loss of consciousness

12References/r45

Guidelines and key sources

›Kwon J, Coimbra R

›Fat Embolism Syndrome After Trauma: What You Need to Know

›Journal of Trauma and Acute Care Surgery, 2024

›PMID 39213184

›Coccolini F, Cremonini C, Moore EE et al

›Thoracic Trauma WSES-AAST Guidelines

›World Journal of Emergency Surgery, 2025

›PMID: PMC12522690

›Godoy DA, Di Napoli M, Rabinstein AA

›Cerebral Fat Embolism: Recognition, Complications, and Prognosis

›Neurocritical Care, 2018

›PMID 28932982

›Talbot M, Schemitsch EH

›Fat Embolism Syndrome: History, Definition, Epidemiology

›Injury, 2006

›PMID 16990059

›Parizel PM, Demey HE, Veeckmans G et al

›Early Diagnosis of Cerebral Fat Embolism Syndrome by Diffusion-Weighted MRI (Starfield Pattern)

›Stroke, 2001

›PMID 11740000

›Alrasheed AS, Elazrag AM, Alqahtani MS, Alabbas F

›Pathophysiology, Clinical Manifestations, and Prognostic Insights of Cerebral Fat Embolism: A Literature Review

›Frontiers in Neurology, 2025

›PMID 41603011

Scoring and diagnostic tools

›Gurd AR and Wilson RI

›Gurd and Wilson diagnostic criteria for FES

Evidence & Review